ARS Pharmaceuticals reported Q4 2025 revenue of $28.1 million, driven by the U.S. commercial launch of neffy. While the company is seeing strong adoption with over 22,500 prescribing HCPs, it recorded a net loss of $41.3 million for the quarter due to significant investments in direct-to-consumer marketing and sales force expansion.

ARS Pharmaceuticals reported strong third quarter 2025 results, with total revenue of $32.5 million, driven primarily by neffy U.S. net product revenue of $31.3 million. The company continues to invest heavily in direct-to-consumer marketing and real-world evidence for neffy, and maintains a strong cash balance of $288.2 million, expected to fund operations through cash-flow break-even. Net loss for the quarter was $51.151 million, or $0.52 per share.

In Q2 2025, ARS Pharmaceuticals generated $15.7M in total revenue, largely from neffy sales in the U.S. and milestone revenue in Germany. Despite the top-line growth, the company posted a net loss of $44.9M due to continued R&D and heavy SG&A spending tied to product promotion.

In Q4 2024, ARS Pharmaceuticals generated total revenue of $86,600,000, which included $6,700,000 in net product revenue from neffy sales in the U.S. and $73,500,000 from collaboration agreements. The company reported net income of $49,900,000 and diluted earnings per share of $0.48. Operating expenses remained controlled, with a focus on commercialization efforts for neffy.

ARS Pharmaceuticals reported a net loss of $19.1 million for Q3 2024. Total revenue was $2.1 million, including $0.6 million in net product revenue from Neffy sales and $1.5 million in collaboration revenue. The company's cash position was strong with $349.6 million on a pro forma basis, adjusted for the $145 million upfront payment from ALK-Abelló.

ARS Pharmaceuticals reported a net loss of $12.5 million for the second quarter of 2024. The company's cash, cash equivalents, and short-term investments were $218.7 million as of June 30, 2024, expected to fund operations for at least three years. The New Drug Application (NDA) for neffy is under review by the FDA, with a PDUFA date in early October 2024.

ARS Pharmaceuticals reported a net loss of $10.3 million for Q1 2024, compared to a net loss of $15.0 million for Q1 2023. The company's cash and securities totaled $223.6 million as of March 31, 2024, which is expected to fund operations for at least three years. The company anticipates potential U.S. launch of neffy in the second half of 2024.

ARS Pharmaceuticals reported its Q4 and full year 2023 financial results, highlighting the submission of response to the FDA's CRL for neffy in early Q2 2024 and successful completion of neffy repeat dose nasal allergen challenge study. The company ended the quarter with $228.4 million in cash, cash equivalents and short-term investments.